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Tyrosinyl1−palmitate-leucine5-enkephalin
(TPLENK)The clinical development of neuropeptides has been limited by a combination of the short plasma half-life of
these drugs and their ultimate failure to permeate the blood brain barrier. Peptide nanoﬁbres have been used
to deliver peptides across the blood brain barrier and in this work we demonstrate that the polymer coating of
peptide nanoﬁbres further enhances peptide delivery to the brain via the intravenous route. Leucine5-
enkephalin (LENK) nanoﬁbres formed from the LENK ester prodrug – tyrosinyl1palmitate-leucine5-enkephalin
(TPLENK) were coated with the polymer – N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-
glycolchitosan (GCPQ) and injected intravenously. Peptide brain delivery was enhanced because the GCPQ coat-
ing on the peptide prodrug nanoﬁbres, speciﬁcally enables the peptide prodrug to escape liver uptake, avoid en-
zymatic degradation to non-active sequences and thus enjoy a longer plasma half life. Plasma half-life is
increased 520%, liver AUC0–4 decreased by 54% and brain AUC0–4 increased by 47% as a result of the GCPQ coating.
The increased brain levels of the GCPQ coated peptide prodrug nanoﬁbres result in the pharmacological activity
of the parent drug (LENK) being signiﬁcantly increased. LENK itself is inactive on intravenous injection.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The difﬁculty in delivering molecules across the blood brain barrier
(BBB) has been identiﬁed as the main reason for the limited develop-
ment of neurotherapeutics [1]. Strategies to deliver peptides intrave-
nously to the brain focus on: a) limiting peptide–hydrogen bonding
with the blood water molecules and thus facilitating the partitioning of
molecules into the lipid endothelial cell membranes of the BBB and
b) stabilising the peptide against plasmadegradation [2]. As suchpeptide
brain delivery strategies revolve around structuralmodiﬁcationmethods
to increase the peptide's lipophilicity, e.g. dimethylation of the tyrosine
residue in D-pen2-D-pen5-enkephalin [3], chlorination of the phenyl
alanine unit in D-pen2-D-pen5-enkephalin [4] or use of lipid prodrugs
of D-ala2-D-leu5 enkephalin (e.g. formation of the C-terminal cholesteryl
ester and N-terminal amidation with 1,4-dihydrotrigonelline) [5]. How-
ever, increasing a drug's lipophilicity has been reported to result in in-
creased plasma clearance and ultimately reduced brain exposure [6]-39 Brunswick Square, London
53 5964.
u).
dical Sciences, University of
.
. This is an open access article underand so the use of lipidisation alone is not a sufﬁciently robust method
of increasing brain exposure. Other peptide brain delivery methods in-
clude stabilising the peptide against degradation by cyclisation and
preventing degradation by both carboxypeptidases and aminopepti-
dases, e.g. the cyclic peptide — D-Pen2-D-pen5-enkephalin [7]. However
despite these published methodologies there are currently no marketed
neuropeptide drugs and hence there is a need for a robustmethod of de-
livering peptides to the brain.
We have recently introduced a nanoparticle–peptide prodrug strate-
gy inwhich the encapsulated lipidic peptide prodrug is stabilised against
metabolic degradation and hence gives rise to a higher level of the actual
peptide in the brain following both intravenous and oral administration
[8]. The amphiphilic nature of the peptide prodrug is hypothesised to as-
sist in its transcytosis across the BBB endothelial cells. We have also
shown that a lipidised peptide prodrug — O-tyrosinyl1palmitate-D-
Alanine2-leucine5-enkephalin (palmitoyl dalargin) forms nanoﬁbres [9]
and that these naked palmitoyl dalargin nanoﬁbres deliver palmitoyl
dalargin to the brain on intravenous injection, resulting in dalargin
anti-nociceptive activity [10]. Dalargin alone, on intravenous injection,
is not detected in the brain and is not active. As well as being used to de-
liver peptides to the brain [10], naked uncoated peptide nanoﬁbres have
been applied as tissue engineering scaffolds [11–14]. However, when
used as drug delivery elements, and when peptide nanoﬁbres arethe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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in the liver at the earliest time point [10]. Such liver deposition would
reduce the drug available for brain uptake. We hypothesised that
since N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-
glycolchitosan (GCPQ) nanoparticles are not taken up by the liver [8],
coating the nanoﬁbre with GCPQ would divert the nanoﬁbres from the
liver resulting in a higher peptide blood residence time and increased
brain uptake. We are aware that GCPQ nanoparticles also adhere to the
luminal side of the blood capillaries [15] at the blood brain barrier and
that such adherence would bring the nanoﬁbres in close proximity to
the target organ. We thus hypothesised that a GCPQ coating on peptide
prodrug nanoﬁbres would beneﬁt brain drug delivery through a variety
of mechanisms and set out to understand the function of the GCPQ coat-
ing on brain delivery. We have used the model leucine5-enkephalin
(LENK) prodrug — tyrosinyl1palmitate-leucine5-enkephalin (TPLENK),
a peptide amphiphile that self assembles into nanoﬁbres, to test our
hypotheses.
2. Materials and methods
2.1. Materials
All reagents and chemicals were obtained from Sigma Aldrich
Chemical Co., Poole, UK, unless otherwise stated. All solvents and acids
were obtained from Fisher Scientiﬁc, Loughborough, UK. Dialysis mem-
branes were purchased from Medicell International Ltd., London, UK.
Deuterium oxide, Methanol-d4 and deuterated palmitic acid (palmitic
acid-d31) were obtained from Cambridge Isotope Laboratories Inc.,
Cheshire, UK. Leucine5-enkephalin and tyrosinyl1-palmitate-leucine5-
enkephalin (TPLENK) were obtained from Peptisyntha Inc., Torrance,
U.S.A. Water for injection was obtained from B. Braun Melsungen AG,
Shefﬁeld, UK. All reagents and chemicals were used without further pu-
riﬁcation and were ≥99% purity. Animals were purchased from Harlan,
Oxfordshire, UK.
2.2. Synthesis and characterisation of chitosan amphiphiles— N-palmitoyl-
N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ)
GCPQ amphiphiles of two differentmolecular weights 6–10 kDa and
50 kDa were synthesised and characterized as described previously by
the acid degradation of glycol chitosan, the palmitoylation of acid de-
graded glycol chitosanwith palmitic acid N-hydroxysuccinimide and ﬁ-
nally alkylation of N-palmitoyl-6-O-glycolchitosan using methyl iodide
[16]. GCPQ6, GCPQ10 and GCPQ50 were thus synthesised (Table 1).
All polymers were characterized using proton nuclear magnetic reso-
nance (1H NMR) analysis and the NMR data used to estimate the level
of palmitoyl grafting and N-methyl quaternary ammonium groups on
the GCPQ polymers [17]. The molecular weights of the ﬁnal polymers
were determined using gel permeation chromatography and multi-
angle laser light scattering as previously described [16,18].
2.3. Nanoﬁbre preparation and characterisation
For the hot plate, tail ﬂick and pharmacokinetics mouse experi-
ments, GCPQ–TPLENK formulations were prepared by probe sonicating
(MSE Soniprep 150, MSE London, UK with the instrument set at 50% ofTable 1
TPLENK–GCPQ nanomedicines.
Samples GCPQ Mn
(kDa)
GCPQ polydispersity
Index
GCPQ mol%
palmitoyl groups
GCPQ mol% quaternar
ammonium groups
TPLENK N/A N/A N/A N/A
GCPQ6 5.62 1.091 20.0 12.4
GCPQ10A 11.88 1.044 18.4 10.5
GCPQ10B 9.11 1.410 15.1 15.1
GCPQ50 41.65 1.473 10.6 11.1its maximum output) GCPQ and TPLENK in the presence of an aqueous
solution of sodium chloride (0.9%w/v) [8], while TPLENK formulations
were prepared by probe sonicating TPLENK in the presence of an aque-
ous solution of glycerol (2.25%w/v). For theComplete Freund's Adjuvant
(CFA) rat experiments a higher dose of TPLENKwas required and hence
a more concentrated TPLENK formulation was prepared. Mice were
dosed at 20 mg kg−1, while rats were dosed at 30 mg kg−1. Hence to
prepare the rat formulations, GCPQ–TPLENK formulations were pre-
pared by dissolving GCPQ and TPLENK in methanol (6 mL). The metha-
nol was then removed by rotary evaporation to produce an amorphous
thin layer of drug-polymer residue. Next, the solid preparation was left
overnight under vacuumand reconstituted inwater for injection BP and
the homogenous suspension was then pH adjusted to pH 7 with NaOH
(1 M). TPLENK alone formulations were prepared by bath sonicating
for 30 min in a solution of glycerol (10% w/v). Formulations for the
in vivo studies were ﬁltered (0.8 μm ﬁlter) prior to administration
and analysed by high pressure liquid chromatography (HPLC) [8] for
TPLENK content after ﬁltration.
Formulations for in vitro experiments were prepared in a similar
manner to those used in the hot plate, tail ﬂick and pharmacokinetics
mouse experiments.
The zeta potential of the samples was determined (Malvern Nano-Zs,
Malvern Instruments, Malvern, UK) by diluting the formulations (a 1 in 7
dilution) prior to conducting themeasurement at room temperature. The
viscosity of the formulationwas assumed to be equivalent to the viscosity
of water. Prior to measurements a zeta potential standard (Zeta transfer
standard, DTS1230, Malvern, UK) was measured and the zeta potential
was found to be in agreementwith the value quoted by themanufacturer.
Particles were imaged by electron microscopy usingmethods previ-
ously reported [18].
Nanomedicine stability studies in plasma were conducted by incu-
bating the formulations in plasma and analysing for TPLENK over time
using methods previously reported.
For plasma protein binding studies, blood was collected from male
CD-1 mice in sterile medical grade polyethylene terephthalate (PET)
tubes, spray coated with tripotassium ethylenediamine tetraacetic acid
(3.6 mg) andmaintained on ice (4 °C) till the plasma could be separated
by centrifugation (3350 g, 15 min at 4 °C, Hermle Z323 centrifuge,
Hermle Labortechnik GmbH, Gosheim, Germany). Freshly prepared
TPLENK formulations (4 mg mL−1 of TPLENK and 10.4 mg mL−1 of
GCPQ, 20 μL) were incubated with plasma (180 μL) at 37 °C for 5 min
[19]. A short incubation time was selected in order to avoid extensive
peptide degradation in the plasma. TPLENK is stable over this period in
plasma as we have shown previously [8]. Samples were centrifuged in
polyallomer tubes (169,000 g, 45 min at 4 °C) using an Optima MAX-E
Ultracentrifuge (BeckmanCoulter UK Ltd., HighWycombe, UK). Immedi-
ately after centrifugation, the supernatant was diluted with methanol
(600 μL) and analysed byHPLC using the isocraticmethod described pre-
viously [8]. The pellet was resuspended in methanol, dimethylsulfoxide
(10:1 v/v, 220 μL) and was also analysed by HPLC [8].
2.4. In vivo studies
2.4.1. Animals
CD-1 male outbred mice (4–5 weeks old, weight = 20–26 g) were
used for the pharmacokinetic and ex-vivo imaging studies, Balb/C maley Peptide–polymer nanoﬁbres (1: 2.6 g g−1)
zeta potential (mV)
Appearance
−32.7 ± 0.06 Clear to slightly translucent
18.8 ± 1.73 Very slightly translucent, yellowish
19.1 ± 1.04 Very slightly translucent, yellowish
19.8 ± 1.3 Slightly translucent
16.8 ± 1.21 Translucent, mildly opaque
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hot plate pharmacodynamics studies and Sprague Dawley rats (6–
8 weeks old, weight = 200–250 g) were used for the Complete
Freund's Adjuvant (CFA) pharmacodynamics studies. The animals
were housed in groups of 4 (rats) or 5 (mice) in plastic cages in con-
trolled laboratory conditions with ambient temperature and humidity
maintained at ~22 °C and 60% respectively and with a 12-hour light
and dark cycle (lights on at 7:00 and off at 19:00). Food and water
were available ad libitum and the animals were acclimatised for
5–7 days prior to experimentation and acclimatised to the procedure
room for 1 h prior to testing (rats for the CFA model) or at least 20 h
prior to testing (mice for the tail ﬂick and hot plate models). All studies
were conducted under a UK Home Ofﬁce Licence and approved by the
local ethics committee.
2.4.2. Pharmacokinetics
Groups of animals (n=5)were intravenously administeredwith ei-
ther sodium chloride (0.9% w/v, 200 μL), TPLENK nanoﬁbres
(4 mg mL−1, 20 mg kg−1) in glycerol (2.25%w/v) or GCPQ–TPLENK
nanoﬁbres in sodium chloride solution (0.9%w/v) composed of GCPQ
(10.4 mg mL−1) and TPLENK (4 mg mL−1) and at a TPLENK dose of
20 mg kg−1.
At various time points, mice were killed and the blood, brain and
liver were sampled. The blood and liver are the main tissues to which
GCPQ distributes on intravenous administration [8] and the brain is
the target organ for these studies. Blood samples (0.5–0.9 mL per
mouse) were collected into evacuated, sterile, spray coated with
tripotassium ethylenediamine tetraacetic acid (3.6 mg), medical grade
PET tubes. Plasma was separated from the blood by centrifugation
(4800 rpm for 15 min at 4 °C, Hermle Z323 centrifuge, Hermle
Labortechnik GmbH, Gosheim, Germany) and was stored at −80 °C
until required for analysis. Brains (0.35–0.45 g) and livers (0.9–1.7 g)
were recovered from mice and immediately frozen in liquid nitrogen
(−80 °C) till required for analysis.
All tissueswere homogenised by adding to each brain or liver HEPES
buffer (0.1 M) (4 mL per gramme of tissue) and the tissues
homogenised using a CryoPrep impactor (Covaris, Herts, UK). For
some early time point brain samples, 14 mL of HEPES buffer was
added per gramme of tissue. To an aliquot of the tissue homogenate
(200 μL) was added an acetonitrile solution of the internal standard
Donezepil (5 ng mL−1, 400 μL). All the samples were orbitally agitated
for 10 min and centrifuged at 3000 rpm for 10 min. A sample of the su-
pernatant (100 μL) was transferred to a 96-well plate using TeMo
(Tecan, Cernusco Sul Naviglio, Italy), the supernatant diluted with
water (80 μL) and analysed by liquid chromatography–mass spectrom-
etry (LC–MS) as described below. The extraction of TPLENK from brain
and liver samples was performed immediately after homogenization
to minimise the in situ degradation of TPLENK.
Plasma samples were diluted 1:2 using HEPES buffer (0.1 M) and a
sample (190 μL) transferred into Micronic tubes using a Freedom Evo
75 (Tecan, Cernusco Sul Naviglio, Italy). Some early time point plasma
samples were diluted with HEPES buffer using a 1:400 dilution (the
5 minute sample), a 1:100 dilution (the 10 minute sample) or a 1:50 di-
lution (the 25 minute sample) instead of a 1:2 dilution. To an aliquot of
the diluted plasma (200 μL)was added an acetonitrile solution of the in-
ternal standard Donezepil (5 ng mL−1, 400 μL). The samples were
orbitally agitated for 10 min and centrifuged at 3000 rpm for 10 min.
A sample of the supernatant (100 μL) was transferred to a 96-well
plate using TeMo, the supernatant was diluted with water (80 μL) and
analysed by liquid chromatography–mass spectrometry (LC–MS) as de-
tailed below.
The plasma standard curve was prepared by a 1:2 dilution of blank
plasma samples with HEPES buffer (0.1 M). An aliquot of the diluted
plasma (190 μL) was transferred to Micronic tubes using a Freedom
Evo 75. A stock solution (1 mg mL−1) was prepared by diluting
TPLENK with dimethylsulfoxide and this stock solution was used toprepare 11 standard solutions with concentrations in the range of
5–10,000 ng mL−1. The standard solutions (10 μL) were used to spike
volumes (190 μL) of the diluted blank plasma using a Freedom Evo 75.
In this way a calibration curve for plasma was prepared within the
range, 0.72 to 1430 ng mL−1. For quality control purposes, two refer-
ence samples were produced by spiking a stock solution of TPLENK
(1 μg mL−1) in blank plasma or acetonitrile, water (1:1 v/v) in order
to produce samples with a ﬁnal concentration of 50 ng mL−1. To each
of these spiked TPLENK samples was added an acetonitrile solution of
the internal standard Donezepil (5 ng mL−1, 400 μL). The standards
were then processed as described above, i.e. centrifuged, the superna-
tant isolated and diluted and analysed by LC–MS.
Blankbrains and liverswereweighed and to eachbrain or liver sample
was added HEPES buffer (4mL per gramme of tissue). The tissue samples
were homogenised using the CryoPrep impactor (impact level 4). An ali-
quot of the homogenate (190 μL) was transferred to Micronic tubes and
using a stock solution of TPLENK (1 mg mL−1) standard solutions were
prepared in acetonitrile,water (1:1 v/v) and aliquots of these standard so-
lutions (10 μL) then used to spike the tissue homogenate samples
(190 μL) using a Freedom Evo 75. In this way a standard curve was pre-
pared within the range 1.25 to 2500 ng mL−1 for both liver and brain
samples. To each of the spiked brain or liver sampleswas added an aceto-
nitrile solution of the internal standard Donezepil (5 ng mL−1, 400 μL).
The samples were then processed as described above, i.e. centrifuged,
the supernatant isolated and diluted and analysed by LC–MS.
LC–MS analysis was performed utilizing an Applied Biosystems
(API4000) mass spectrometer in the positive-ion/Turbo Ionspray
mode (Applied Biosystems, Streetsville, Canada). The source tempera-
ture was set at 600 °C. Samples (5 μL) were injected using Presearch
PAL CTC Autosampler (CTC Analytics AG, Zwingen, Switzerland) and
gradient elution followed using an Agilent HP 100 HPLC (Agilent Tech-
nologies, Waldbronn, Germany), which was connected to a Thermo
Gold (Aqua) column (30 × 3 mm, particle size = 3 μm, Thermo
Scientiﬁc, Runcorn, UK). The column temperature was set at 50 °C.
The mobile phase ﬂow rate was set at 1 mL min−1. The mobile
phase comprised: mobile phase A, consisting of formic acid: water
(0.1:99.9 v/v) and mobile phase B consisting of formic acid: acetonitrile
(0.1:99.9 v/v). The gradient elution sequence was: t = 0 min, 20% mo-
bile phase B; t = 0.8 min, 90%mobile phase B; t = 1.8 min, 20% mobile
phase B. The retention time for the analytes was: Donezepil = 0.85min
and TPLENK = 1.26 min. The identifying species were: Donezepil Q1/
Q3 = 380.3/91.2 and TPLENK Q1/Q3 = 794.6/136.0.
The stability of TPLENK in biological matrixes and recovery were
both tested prior to the start of the analyses and the recovery of
TPLENK from spiked plasma, brain and liver samples was 94.5, 99.6
and 95.3% respectively.
The pharmacokinetic parameters of TPLENK nanoﬁbres and
GCPQ–TPLENK-nanomedicines were calculated by applying non-
compartmental pharmacokinetic analysis to the plasma con-
centration-time data using MicroCal Origin 6.0 software (Microcal,
Buckinghamshire, UK).
2.4.3. Multiphoton microscopy
Deuterated GCPQ10 (dGCPQ10,Mw= 11.97 kDa,Mn= 13.99 kDa)
and deuterated GCPQ6 (dGCPQ6, Mw = 9.11 kDa, Mn = 8.57 kDa)
were synthesised as previously described [16] and nanoparticles pre-
pared as described above. Mice were intravenously injected with
dGCPQ (10.4 mg mL−1, 200 μL, 85 mg kg−1) and were subsequently
killed at various time points. Organs were harvested and stored in neu-
tral buffered formalin (10% v/v, 15mL). All samples formultiphoton im-
aging were placed between two glass coverslips using Paraﬁlm spacers
following the same procedure as described previously [16,20].
CoherentAnti-Stokes RamanScattering (CARS)microscopywasper-
formed using a custom built imaging system based on a modiﬁed com-
mercial confocal laser scanning microscopy and a synchronised dual-
wavelength picosecond laser source. Laser excitation was provided by
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pumped with a frequency doubled Nd:Vandium picosecond oscillator
(High-Q Laser Production GmbH). The pump laser generated a 6 ps,
76 MHz pulse train at 532 nm with adjustable output power up to
10 W. The OPO produced collinear signal and idler beams with perfect
temporal overlap and provided continuous tuning over a range ofwave-
lengths. The signal beam was used as the pump, ranging from 670 to
980 nm and the pump laser was used as the Stokes beam at 1064 nm.
The maximum combined output power of the signal and idler was ap-
proximately 2 W and average power at the sample was between
15 mW and 30 mW. Two Photon Fluorescence (TPF) microscopy was
undertaken using a mode-locked femtosecond Ti:sapphire oscillator
(Mira 900D; Coherent, USA) which produced 100-fs pulses at 76 MHz.
The central wavelength of the fs beam was 800 nm with an average
power at the sample that was attenuated to between 5 and 30 mW.
Imaging was performed using a modiﬁed commercial microscope
(IX71 and FV300, Olympus UK). To minimise light loss the galvanome-
ter mirrors were replaced with silver mirrors and the tube lens was re-
placed with aMgF2 coated lens. The laser beamswere directed onto the
scanning confocal dichroic which was replaced by a silver mirror with
high reﬂectivity throughout the visible and near infrared regions
(21010, Chroma Technologies, USA). All imaging was performed using
a 60×, 1.2 NA water immersion objective (UPlanS Apo, Olympus UK).
The epi-CARS signal was collected using the objective lens and sep-
arated from the pump and Stokes beams by a long-wave pass dichroic
mirror (z850rdc-xr, Chroma Technologies, USA) and directed onto a
second R3896 photomultiplier tube at the rear microscope port. The
CARS signal was isolated at the photodetector using a single band-
pass ﬁlter centred at the anti-Stokes wavelength. The epi-detected TPF
signal was detected in a similarmanner, undergoing spectral separation
from the 800 nm excitation beam by a dichroic mirror before being iso-
lated by a band pass ﬁlter.
2.4.4. Pharmacodynamics
Two acute pain models (the tail ﬂick bioassay and the hot plate
method) and one chronic pain model [the Complete Freund's Adjuvant
(CFA) model] were used. Antinociception in the tail ﬂick bioassay and
hot plate experiments was assessed in mice, following the intravenous
injection of a sodium chloride control (0.9% w/v), TPLENK nanoﬁbres
in glycerol (2.25% w/v) or a GCPQ–TPLENK formulation in sodium chlo-
ride (0.9%w/v). Antinociception in the CFA experimentswas assessed in
rats following the administration of the vehicle (glycerol— 10% w/v) or
a GCPQ–TPLENK formulation in pH adjusted (pH = 7) water for injec-
tion or TPLENK nanoﬁbres in glycerol (10% w/v).
2.4.4.1. Tail ﬂick bioassay. Antinociception was evaluated using the tail
ﬂick warmwater bioassay [8,16] in which mice are subjected to a ther-
mal stimulus over a 10 s time frame and their response latency (a sharp
removal of the tail from the stimulus) to the thermal stimulus mea-
sured. Mice not responding within 5 s were excluded from further test-
ing and the baseline latency wasmeasured for all mice 2 h prior testing.
The baseline latency was 2.44 ± 0.62 s. An analgesic responder was de-
ﬁned as onewhose response tail ﬂick latencywas two ormore times the
value of the baseline latency and the timeswere expressed as a percent-
age of the maximum possible effect (MPE). A mouse showing a MPE
was a mouse achieving the maximum tail ﬂick latency to thermal stim-
uli of 10 s. Mice were evaluated by a female researcher.
2.4.4.2. Hot plate bioassay. The hot-plate bioassaywas also used to assess
antinociception after intravenous administration. A glass cylinder
(16 cm high, 16 cm in diameter) was used to keep the mouse on the
heated surface of a hot plate (Harvard Apparatus, Kent, UK) that was
maintained at 60 ± 0.1 °C. The response latency times until the
mouse ﬁrst exhibited nociceptive behaviour (licking of the paw or an
escape jump) were recorded using a digital stopwatch capable of mea-
suring 1/100th of a second. The cut-off timewas 30 s to avoid damage tothe animals' paws and animals were excluded from testing if they had
baseline latencies greater than 15 s. Three repeated measurements
were recorded for each timepoint,with 60 s between testing and the re-
sponse times were then converted %MPE values in a similar manner as
highlighted above. Mice were evaluated by a female researcher.
2.4.4.3. Complete Freund's adjuvant chronic pain model. Rats received an
intraplantar injection of 100 μL of Complete Freund's adjuvant (CFA),
(Mycobacterium tuberculosis heat killed suspended in 85% parafﬁn oil
and 15%mannidemonooleate 1 mg/mL) using a glass Hamilton syringe
with a 25G needle. CFA caused hind paw oedema and mechanical hy-
persensitivity as evaluated 24 h after the CFA injection.
Mechanical hypersensitivity was evaluated as previously described
[21]. Rats were individually placed on an elevated plastic mesh
(0.5 cm2 perforations) in a clear plastic cage. Two habituations to the
evaluation chambers for at least 5 min duration each were performed
on two different days. A baseline measurement was taken on test day
pre-CFA. Mechanical hypersensitivity was assessed by the sensitivity
to the application of von Frey hairs (Ugo Basile, Varese, Italy). The von
Frey ﬁlaments (1.4, 2, 4, 6, 8, 10, 15, 26 g) were presented perpendicu-
larly to the plantar surface of the injected paw in ascending order, and
held in this position for 5 s with enough force to cause a slight bend in
the ﬁlament. Positive responses included an abrupt withdrawal of the
hind paw or response was noted if the paw was sharply withdrawn or
there was ﬂinching upon application of the hair. Once a positive with-
drawal response was established, the paw was retested, starting with
the next descending von Frey hair until no response occurred. The low-
est amount of force required to elicit a response was recorded as the
paw withdrawal threshold (g) [22].
Mechanical allodynia was deﬁned as a signiﬁcant decrease in with-
drawal thresholds to von Frey ﬁlament application. The 26 g hair was
selected as the upper limit cut-off for testing.
To test formulation effects on mechanical allodynia, rats were
evaluated for thresholds 5 days after CFA injection; they were then
randomised according to their threshold values and injected with for-
mulations. Rats were evaluated by a female observer, blinded to the
treatments.
2.5. Statistical analysis
Statistical analysis was performed via a one-way ANOVA test using
Minitab 16 (Minitab Ltd., Coventry, UK) followed by Tukey's post-hoc
test. A two-way ANOVA test was used to analyse the CFA data.
3. Results
3.1. Peptide nanoﬁbre morphology
Aqueous dispersions of TPLENK and TPLENK–GCPQ, present as
translucent nanoparticle dispersions containing peptide nanoﬁbres
(Table 1 and Fig. 1). Fibres are 0.5–2 μm in length and 20–30 nm
in width. TPLENK nanoﬁbres are anionic in nature at neutral pH
(Table 1) and appear as twisted aggregates (Fig. 1c), while GCPQ–
TPLENK formulations consist of positively charged nanoﬁbres at neutral
pH (Table 1) and were devoid of the periodic twists seen in the TPLENK
alone formulations (Fig. 1). GCPQ–TPLENK nanoﬁbres also presented as
a less aggregated morphology (Fig. 1). Peptide amphiphiles have been
shown to self assemble into nanoﬁbres [9,10,23] and peptide nanoﬁbres
arise from the hydrophobic association of the peptide's hydrophobic
units and the hydrogen bonding of the peptide amino acids in the pep-
tide backbone to form a beta sheet, with the peptide beta sheet wrap-
ping tightly around the peptide nanoﬁbre shaft [10]. The inclusion of
GCPQ coats the nanoﬁbres, as evidenced by the shift in zeta potential
from a negative to a positive value on inclusion of GCPQ (Table 1).
These are the ﬁrst reported images of polymer coated peptide
nanoﬁbres (Fig. 1a, b and d) and the ﬁrst evidence of a polymer coating
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dence that the nanoﬁbre morphology persists even in the presence of
a self assembling amphiphilic polymer, such as GCPQ. The GCPQ coating
promotes spatial repulsion between individual ﬁbres (Fig. 1), presum-
ably via electrostatic repulsions (Table 1). The molecular weight (6–10
and 50 kDa) of the GCPQ coating does not affect the polymer coated
nanoﬁbre morphology.
3.2. Plasma stability of peptide nanoﬁbres
LENK is a linear endogenous pentapeptide, which binds selectively
to the delta opioid G-protein coupled receptors in the brain; the drug
has a short plasmahalf-life of 3min in humans after intravenous admin-
istration [24] and is degraded completely, in plasma in vitro studies,
within 1.5 h [8]. Here we report that GCPQ50–TPLENK and TPLENK for-
mulations do not undergo peptide degradation after an 8 h incubation
period in plasma (Fig. 2a). This is in accordancewith our previous report
where we showed that TPLENK and GCPQ10–TPLENK formulations
show exceptional in vitro stability in plasma [8]. It is clear, as we have
established with palmitoyl dalargin nanoﬁbres [10], that the nanoﬁbre
arrangement prevents access of peptidase enzymes to the peptide, pre-
serving the peptide in the plasma.
Fig. 2b shows that the GCPQ coating also suppresses plasma protein
binding as the amount of unbound peptide recovered in these in vitro ex-
periments increases from 4% to over 16% in the presence of the polymer
coating. A higher unbound fraction of the peptide nanoﬁbres should im-
prove across the blood brain barrier transport of the peptide prodrug.
3.3. Pharmacokinetics
Blood and tissues (brain and liver) were sampled at the following
time points 5, 10, 25, 45, 90, 240, 480 and 1440 min but only the ﬁrst
4 h are shown in Fig. 3, as tissue levels post the 240 minute time
point were less than 0.05% of the peak values. We focused on the
blood, brain and liver as the brain is the target organ and the intrave-
nous injection of GCPQ nanoparticles results in distribution to the
liver (2% of the injected dose) kidneys (6% of the injected dose)
and bladder (4% of the injected dose) at the tmax (5 min) with less
than 0.3% of the injected dose distributing to the other major organs
(spleen, lungs, heart) [% dose = (tissue concentration X tissue
weight) / dose weight] [8].
On intravenous injection, TPLENK nanoﬁbres were cleared rapidly
from the plasma with 6.4% of the dose found in the liver at the earliest
time point and the TPLENK nanoﬁbre formulation had a plasma half-
life of 1.18 h (Table 2). This compares favourably with LENK's in vivo
plasma half life of 3 min [24]. TPLENK also distributed to the brain
with 0.07% of the injected dose present in the brain at the tmax
(5 min). These levels compare well with the intravenous morphine
which gives a peak level of 0.02% in the brain at the tmax (30 min)
[25]. This brain delivery data is in line with data we have presented on
palmitoyl dalargin nanoﬁbres [10]. Palmitoyl dalargin nanoﬁbres deliv-
ered palmitoyl dalargin to the brain on intravenous dosing and 0.2% of
the intravenous dose is found in the brain at the tmax (5 min) [10]. It
is thus clear that peptide nanoﬁbres offer a robustmethod for delivering
peptide drugs to the brain.What is not clear however is the exactmech-
anism of peptide nanoﬁbre transcytosis across the brain endothelial
cells and what proportion of the intact peptide nanoﬁbres cross theFig. 1 Microscopy images of TPLENK formulations: a) transmission electronmicrograph of
GCPQ10 (10.4 mg mL−1)–TPLENK (4 mg mL−1) nanoﬁbres (GCPQ, TPLENK molar ra-
tio = 0.017), b) transmission electron micrograph of GCPQ50 (10.4 mg mL−1)–TPLENK
(4 mg mL−1) nanoﬁbres (GCPQ, TPLENK molar ratio = 0.005), c) transmission electron
micrograph of TPLENK (4 mg mL−1) nanoﬁbres, d) transmission electron micrograph of
GCPQ6 (10.4 mg mL−1)–TPLENK (4 mg mL−1) nanoﬁbres (GCPQ, TPLENK molar ra-
tio = 0.36), All nanoﬁbres are dispersed in NaCl solution (0.9% w/v) apart from TPLENK
alone which is dispersed in glycerol solution (2.25% w/v).
Fig. 2. In vitro peptide amphiphile stability (mean± SD). a) The stability of GCPQ–TPLENK
nanomedicines in plasma (50% v/v), ♦ = TPLENK (4 mg mL−1), ■ = GCPQ50
(10.3 mg mL−1)–TPLENK (4 mg mL−1). b) Plasma protein binding of GCPQ–TPLENK
nanoﬁbres [TPLENK (4 mg mL−1) and GCPQ (10.4 mg mL−1)]. The peptide in the pellet
is plasma protein bound while the peptide in the supernatant is the unbound fraction of
the peptide. Signiﬁcant differences * = p b 0.05 versus TPLENK.
92 A. Lalatsa et al. / Journal of Controlled Release 197 (2015) 87–96brain endothelial cells and what proportion of disaggregated amphi-
philic peptide monomers cross the brain endothelial cells.
Lipophilicity tends to increase the clearance of the drug from the
plasma, once again limiting the amount of drug available for brain up-
take [6]. The main plasma clearance organ is the liver and GCPQ
(Mw= 10–20 kDa) is not taken up by the liver to an appreciable extent
with about 2% of an intravenous dose of GCPQ nanoparticles present in
the liver 5 min after dosing [8]. This level of liver uptake is low when
compared to other intravenous injections of nanoparticle formulations.
For example 40% of the doxorubicin sorbitan monostearate niosome
dose is seen in the liver 10 min after intravenous dosing [26] and 55%
of a liposomal albumin dose is found in the liver 10 min after intrave-
nous dosing [27]. Based on the low level of liver uptake of GCPQ nano-
particles [8] we hypothesised that coating TPLENK nanoﬁbres with
GCPQ should prevent the liver uptake of TPLENK nanoﬁbres. On coating
TPLENK nanoﬁbres with GCPQ10 and GCPQ50, plasma protein binding
is reduced (Fig. 2b) and on administering TPLENK nanoﬁbres coated
with GCPQ10, liver AUC0–4h is reduced by 54%, plasma half-life is ex-
tended over 5 fold, and the brain AUC0–4h increased by 47% (Table 2,
Fig. 3). With a GCPQ50 coating, the liver exposure of TPLENK was not
signiﬁcantly changed but the plasma half-life was extended over 300%
and the brain AUC increased by 24% (Table 2, Fig. 3). Although animals
were not perfused, themajority of the brain levelmeasuredwas present
in the brain parenchyma and not in the brain vasculature. This was con-
ﬁrmed by using published brain vasculature volumes of 12 μL per g−1
[28]. Using these values, the level of drug in the brain parenchyma at
the earliest time point sampled, was estimated to be 66% of the overall
brain level for TPLENK, 64% of the overall brain level for GCPQ10–TPLENK and 62% of the overall brain level for GCPQ50–TPLENK. The in-
creased distribution of TPLENK to the brain using GCPQ50–TPLENK and
GCPQ10–TPLENK is due to the slower plasma clearance of these
nanoﬁbre formulations by various hepatic and extra-hepatic mecha-
nisms. In the case of GCPQ10–TPLENK, there is an indication that the re-
duced hepatic clearance contributes to the higher level of TPLENK in the
plasma from this formulation, as there is a signiﬁcantly lower level of
TPLENK in the liver when GCPQ10–TPLENK is administered when com-
pared to the intravenous administration of TPLENK alone.
We have previously shown that GCPQ nanoparticles largely avoid
the liver [8] and here we show for the ﬁrst time that GCPQ10 coating
of nanoﬁbres also results in liver avoidance with only 1.6% of the intra-
venous dose of TPLENK being found in the liver at the earliest time
point, on the intravenous injection of GCPQ10–TPLENK nanoﬁbres
(Fig. 3). This reduced uptake by the liver is one of the reasons for the im-
provement in brain permeation found for these nanoﬁbers. GCPQ10–
TPLENK nanoﬁbres distribute more drug to the brain when compared
to GCPQ50–TPLENK nanoﬁbres (Fig. 3), with signiﬁcant differences
noted at the 10 minute time point, and one reason for this is the com-
paratively increased clearance of GCPQ50–TPLENK nanoﬁbres by the
liver (Fig. 3c).3.4. CARS imaging
In order to understand the brain localisation of intravenously
injected GCPQ nanoparticles we used CARS microscopy to image deu-
terated GCPQ nanoparticles. Using CARS microscopy [15,20], we
visualised dGCPQ10 and dGCPQ6 particles in biological tissues after in-
travenous administration (Fig. 4). Fig. 4a and b shows the distribution of
intravenously injected empty dGCPQ6 and dGCPQ10 nanoparticles
distributed in the brain thalamus vasculature with some evidence of
penetration into the brain parenchyma with dGCPQ10 nanoparticles
(Fig. 4b). LENK is a mixed (δ and μ) opioid receptor agonist with a ten
fold selectivity for the δ opioid receptor, when compared to the μ opioid
receptor [29]. Mu opioid receptors are present in the thalamus and spe-
ciﬁcally the nucleus submedius of the medial thalamus and are partly
responsible for the anti-nociceptive response [30]. Thus the appearance
of dGCPQ10 and dGCPQ6 nanoparticles in the vasculature of the thala-
mus on intravenous administration should mean that intravenously
injected GCPQ coated TPLENK nanoparticles should facilitate the deliv-
ery of TPLENK and in turn LENK to the site of thesemu opioid receptors,
with thalamus vasculature TPLENK crossing the brain endothelial cells
and LENK being released by esterases. We have previously shown phar-
macologically relevant mouse brain levels of LENK on intravenous ad-
ministration of GCPQ10–TPLENK [8] and the localisation of the
positively charged GCPQ10 nanoparticles to the luminal vascular walls
of the mouse brain [31].
Delta opioid receptors are present in all regions of the central ner-
vous system of humans with high levels in the cerebral cortex, nucleus
accumbens and caudate nucleus [32]. Hencewhen considering translat-
ing this technology to humans, we have sufﬁcient reason to assert that
delta opioid receptors will also be accessible to intravenously injected
TPLENK nanoparticles coated with GCPQ10.
Intravenously injected dGCPQ10 and dGCPQ6 nanoparticles are seen
in the liver hepatocytes (Fig. 4c) and liver hepatocellular spaces (Fig. 4d)
respectively. The appearance of dGCPQ10 nanoparticles within the liver
hepatocytes demonstrates that the uptake of dGCPQ10 particles
operates through different mechanisms when compared to most intra-
venously injected particles, which are found predominantly within
the Kupffer cells [33] of the liver and are not normally detected in the
hepatocytes. Kupffer cell localisation of other intravenously injected
nanoparticles such as phospholipid liposomes is a result of opsonisation
(labelling within the blood with blood proteins) and rapid clearance by
the liver Kupffer cells [33,34]. The different uptake mechanism, experi-
enced by GCPQ nanoparticles could be responsible for the very low liver
Fig. 3. The biodistribution of TPLENK nanoﬁbre formulations after the intravenous admin-
istration of TPLENK nanoﬁbres (20 mg kg−1) to mice (mean ± s.d., n = 4): a) plasma
levels following the administration of TPLENK (4 mg mL−1) nanoﬁbres (♦) in glycerol
(2.25% w/w), GCPQ50 (10.4 mg mL−1)–TPLENK (4 mg mL−1) nanoﬁbres (■) in NaCl
(0.9%w/v), GCPQ10 (10.4 mg mL−1)–TPLENK (4 mg mL−1) nanoﬁbres (●) in NaCl
(0.9%w/v); b) brain levels following the intravenous administration of TPLENK nanoﬁbres
(20 mg kg−1), symbols as in Fig. 3a; c) liver levels following the intravenous administra-
tion of TPLENK nanoﬁbres (20 mg kg−1), symbols as in Fig. 3a. * = Signiﬁcant differences
between TPLENK nanoﬁbres and all GCPQ–TPLENK formulations (p b 0.05), += Signiﬁ-
cant differences between GCPQ10–TPLENK and all other formulations (p b 0.05).
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nitely warrant further study.3.5. Pharmacodynamics
In an effort to understand whether the increased brain delivery of
GCPQ–TPLENK formulations (Fig. 3b) would result in an increase in
LENK activity, we evaluated the TPLENK formulations in both acute
(tail ﬂick and hot plate) and chronic (CFA) pain models (Fig. 5). All
TPLENK formulations produced anti-nociceptive activity in the mouse
tail ﬂick bioassay and the GCPQ coated nanoﬁbre formulations were
more active than the TPLENK nanoﬁbres alone (Fig. 5a). There was no
anti-nociceptive activity recorded for the control samples (NaCl,
GCPQ10 alone and LENK). While GCPQ50–TPLENK, GCPQ10–TPLENK
and GCPQ6–TPLENK formulations all produced the maximum possible
antinociception between 60 and 90min after dosing (Fig. 5a), the activ-
ity of TPLENK nanoﬁbres alone was inferior to that recorded for the
GCPQ coated TPLENK nanoﬁbre formulations.GCPQ 10–TPLENK was also active in the hot plate assay (Fig. 5b).
Once again LENK was not active in this assay. As can be seen from
Fig. 5b, learning is observed during the hot-plate bioassay after 4 to 5
measurements [35] as evidenced by a change from a lick of the paws
in test naive animals to an escape jump in less naive animals. This learn-
ing behaviour manifests as a progressive shortening of the jumping re-
action time (Fig. 5c) and a disappearance of the licking behaviour.
GCPQ6–TPLENK was active in the CFA model whereas TPLENK
alone was not active in this chronic pain model. GCPQ6 was used in
the CFA assay instead of GCPQ10 or GCPQ50 as this polymer, being
less viscous, enabled a higher concentration of TPLENK to be formulated
(15 mgmL−1) and thus a higher dose to be administered to the rat CFA
model. The fact that TPLENK nanoﬁbres showan inferior responsewhen
compared to the polymer coated nanoﬁbre formulations provides fur-
ther proof for the hypothesis that a polymer coating on peptide
nanoﬁbres promotes brain delivery of peptides.
Althoughwith all TPLENK formulations, TPLENKwas rapidly cleared
from the plasma and the brain, with very low levels recorded 45 min
after dosing (Fig. 3), anti-nociception after the administration of
TPLENK formulations could be detected at the 25 minute time point
and the activity peaked at the 60–90 minute time points (Fig. 5). This
is explained by the fact that TPLENK is acting as a prodrug.We have pre-
viously shown that peak levels of LENK following the intravenous ad-
ministration of GCPQ10–TPLENK were achieved at the 90 minute time
point in accordance with the peak activity of the formulation [8]. The
delayed pharmacodynamic response is further evidence that TPLENK
is indeed acting as a prodrug. Ester prodrugs are rapidly cleaved to the
parent drug: being completely cleaved within 30 min in the case of
the phosphate ester prodrug of the anti-fungal agent, ravuconazole
[36], or the (glycyl, glutamyl)diethyl ester prodrug of the anti-tumour
agent, S-(N-p-chlorophenyl-N-hydroxycarbamoyl)glutathione [37].
4. Discussion
The delivery of peptides to the brain is an area fraughtwith difﬁculty
due to the rapid degradation of peptides in the blood and brain and their
hydrophilicity which prevents them crossing the BBB [1,38]. LENK is a
case in point; LENK is a pentapeptide opioid receptor agonistwith selec-
tivity for the δ opioid receptors [29] and this drug is rapidly degraded
and does not cross the blood brain barrier in sufﬁcient quantities to be
active; it is thus only active following intracerebroventricular adminis-
tration at a high dose [39]. LENK is thus a good model to use to study
peptide delivery. Our interest in this area has led us to introduce two
new concepts: a) the use of nanoﬁbre forming prodrugs [10] and b) a
polymer encapsulated prodrug nanoparticle [8]. The prodrug nanoﬁbre
formulation of palmitoyl dalargin results in peptide prodrug nanoﬁbres
distributing to the brain and produces an anti-nociceptive response on
intravenous administration, while dalargin is inactive via the intrave-
nous route [10]. The LENK prodrug is TPLENK and this prodrug on en-
capsulation within chitosan amphiphile (GCPQ) nanoparticles, yields
pharmacological levels of LENK on oral and intravenous administration,
while LENK itself is inactive via the intravenous route [8]. In the current
work we set out to examine the precise role of GCPQ in the GCPQ–
TPLENK formulations. Here we hypothesised that the GCPQ in GCPQ–
TPLENK formulations would result in an altered biodistribution of
TPLENK, principally stemming from reduced liver uptake. This reduced
liver uptake would eventually favour brain delivery of TPLENK and
a pharmacological response. We have found that TPLENK forms
nanoﬁbres either alone or when coated with GCPQ (Fig. 1). Nanoﬁbres
are less aggregated when coated with GCPQ (Fig. 1a, 1b and 1d) and
coated ﬁbres are 1–2 μm in length and 20 nm in diameter. Nanoﬁbres
coated with GCPQ10 avoid liver uptake resulting in an increase in plas-
ma residence and an increased delivery to the brain, increasing the plas-
ma half life by over 5 fold and the brain exposure of TPLENK by 47%
(Fig. 3 and Table 2). Coating the TPLENK nanoﬁbres with GCPQ10 (mo-
lecular weight= 10 kDa) was preferable, with respect to brain delivery
Table 2
TPLENK intravenous dosing pharmacokinetics.
Pharmacokinetic
parameters
Intravenous administration of a 20 mg kg−1
dose
TPLENK GCPQ10–TPLENK GCPQ50–TPLENK
Plasma AUC0–4 (μg h mL−1)a 12.22 23.75 21.35
Plasma Cmax (μg mL−1) 39.16 109.50 82.96
t 1/2 (h)b 1.18 6.18 3.88
Vd (L kg−1)c 2.72 7.40 5.07
Clearance (L h−1 kg−1) 1.6 0.83 0.91
Brain AUC0–4 (μg h mL−1) 0.187 0.275 0.231
Brain Cmax (μg g−1) 0.697 1.374 1.736
Brain tmax (h) 0.083 0.083 0.083
Liver AUC0–4 (μg h mL−1) 7.238 3.322 4.743
Liver Cmax (μg g−1) 32.60 8.20 22.28
Liver tmax (h) 0.083 0.083 0.083
a AUC0–4 — area under the concentration time curves 4 h post administration.
b t ½ — half-life.
c Vd— volume of distribution.
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Fig. 4. Three-dimensional false-colour reconstructions of CARS (a, b and d) and TPF com-
binedwith CARS (c)microscopy images ofmouse tissue samples after intravenous dosing
with dGCPQ10L and dGCPQ6L nanoparticles [15,16]. Red contrast was obtained either
from TPF or from CARS with the pump and Stokes beams tuned to excite the CH-stretch
(2845 cm−1), yielding strong signal from lipids within the sample and thus providing de-
tailed sub-cellular structural information. Green contrastwas obtainedwith thepumpand
Stokes beams tuned to excite the CD-stretch (2100 cm−1), with strong signal detected
from the dGCPQ. Theweak signal from the non-resonant background in the green channel
was several orders of magnitude less intense than the strong CD signal from the dGCPQ,
and was therefore readily screened out by thresholding the images. By combining the
red and thresholded green channels [15], it was possible to pinpoint co-localised signal
arising from dGCPQ, thus allowing precise identiﬁcation of the location of dGCPQ within
the sample. a) Thalamus region of mouse brain, 60 min after an IV dose of dGCPQ6
(85 mg kg−1, 10.4 mg mL−1). Red blood cells (RBC) can be seen within a blood vessel
(green arrows) as can the dGCPQ6 signal (yellow arrows) within the perivascular spaces.
b) Thalamus region of mouse brain, 60 min after an IV dose of GCPQ10 (85 mg kg−1,
10.4mgmL−1), with dGCPQ10 signal (yellow arrows) clearly seen in the brain parenchy-
ma. c) Mouse liver 60 min after the intravenous dosing of GCPQ10 nanoparticles
(85 mg kg−1, 10.4 mg mL−1), strong ﬂuorescence signal from red blood cells resulting
from increased autoﬂuorescence as a result ofﬁxation, is seen clusteringwithin blood ves-
sels (RB, green arrows) and the deuterated particle signal was found to be located within
the cytoplasm of hepatocytes (yellow arrows). Kupffer cells (labelled KC) are outlined in
grey to ease visualisation. d) Mouse liver 60 min after the intravenous dosing of dGCPQ6
nanoparticles (85 mg kg−1, 10.4 mg mL−1), lipid droplets are clearly seen (a selection of
which have been labelled ‘LDs’ with white arrows) and the deuterated particle signal
was found to be located within the hepatocellular spaces (yellow arrows). Since the deu-
terated signal contribution in dGCPQ arises only from the palmitoyl chain, there is still CH
signal detected from the remaining CH2 bondswithin the nanoparticles, hence there is co-
localised signal associated with dCGPQ in the red CH and the green CD images.
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weight = 50 kDa) and the reason for this is unclear at present. Based
on our current (Figs. 3 and 5) and previous [8] data, we know that
TPLENK is rapidly converted LENK in the plasma and liver and that the
prodrug TPLENK exerts its activity via the LENK parent drug.
Previous to our own work, peptides were converted to more hydro-
phobic variants to enable them to be delivered to the brain [3,4] and
favourable results were not always guaranteed as lipidisation promotes
drug clearance [6], depleting the plasma of drug and hence the brain of
drug subsequently. The system thatwe have described involves forming
a nanoﬁbre with a cationic and amphiphilic liver avoiding polymer —
GCPQ (which is eventually excreted by the kidneys) [8] to form the
liver avoiding nanoﬁbres with an extended plasma half life. The ulti-
mate result is an increase in the level of coated peptide nanoﬁbre in
the blood and we know that this GCPQ coating promotes adhesion to
the luminal vasculature surfaces of the brain [15], a fact that will bring
these drug ﬁbres in close proximity to the target site — the brain
(Fig. 4b). This strategy produces increased brain delivery and activity
from peptides, which are otherwise inactive on intravenous dosing.
5. Conclusions
The use of lipidic ester peptide prodrug nanoﬁbres coated with
chitosan amphiphiles (GCPQ) is a viable strategy for the delivery of
peptides to the brain following intravenous administration. These poly-
mer coated nanoﬁbres avoid plasma protein binding and liver uptake to
delivermore of the peptide prodrug to the brain and produce a pharma-
cological response from peptides that are otherwise inactive via the in-
travenous route.
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